Company Focus
Ipsen
Latest Ipsen News
Pharmaceutical
Ipsen has reported second-quarter 2025 sales of 901 million euros ($980 million), up 8% from the same period a year ago. Core earnings per share rose 27% to 6.07 euros ($6.60) as strength in rare disease products offset flat performance in oncology. 31 July 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Ipsen
Pharmaceutical
Costco has confirmed it will not sell the abortion pill mifepristone, which is sold under the Mifeprex brand, in any of its US pharmacy locations. The decision comes after pressure from faith-based advocacy groups including Alliance Defending Freedom. With Costco’s stance set, these groups are now focusing on CVS and Walgreens. 15 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
A first-of-its-kind study from UK pharm major AstraZeneca and Macmillan Cancer Support into the barriers around access to the latest biomarker testing for cancer in the UK has been published in Future Oncology. 15 August 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s Fasenra (benralizumab) for use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). 14 August 2025
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Pharmaceutical
China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, with Tasly Holding Group and Pan-Lin Asset Management leading the round. 14 August 2025
Biotechnology
Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed president, chief executive (CEO) and to the board of directors. 14 August 2025
Biotechnology
China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China, as per the pre-specified study protocol. 14 August 2025
Pharmaceutical
Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 million kroner ($1,915 million) in the first six months of 2025. Growth in the USA and Europe was the driver of this strong performance. 14 August 2025
Pharmaceutical
Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately negotiated block trade, raising at least $174 million. The move is part of a plan to extend its cash runway while meeting a $100 million milestone owed to Arrowhead. 14 August 2025
Latest In Brief for Ipsen
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim announced that Hernexeos (zongertinib tablets) has been recommended as a preferred subsequent therapy option for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with ERBB2 (HER2) mutations who received prior systemic therapy in the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for non-small cell lung cancer (Version 8), updated on August 15, 2025 16 August 2025
Latest Relevant Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze